NASDAQ : MIRM
Mirum Pharmaceuticals, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 85 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 5.52B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 5.57B |
| Enterprise Value | 5.89B |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 3, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 64.93M |
| Shares Outstanding | 64.93M |
| Shares Change (YoY) | +15.36% |
| Shares Change (QoQ) | +7.69% |
| Owned by Insiders (%) | 1.33% |
| Owned by Institutions (%) | 100.53% |
| Float | 56.39M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 9.01 |
| Forward PS | 7.44 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 9.53 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 2.86 |
| Quick Ratio | 2.62 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -7.16 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -702.97% |
| Return on Assets (ROA) | -6.79% |
| Return on Invested Capital (ROIC) | -9.07% |
| Return on Capital Employed (ROCE) | -11.70% |
| Weighted Average Cost of Capital (WACC) | 6.88% |
| Revenue Per Employee | $1.43M |
| Profits Per Employee | -$1.99M |
| Employee Count | 433 |
| Asset Turnover | 0.70 |
| Inventory Turnover | 4.64 |
Taxes
| Measure | Value |
|---|
| Income Tax | 2.67M |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.61 |
| 52-Week Price Change | +18.02% |
| 50-Day Moving Average | 89.72 |
| 200-Day Moving Average | 98.54 |
| Relative Strength Index (RSI) | 50.29 |
| Average Volume (20 Days) | 710,635 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 6.66M |
| Short Previous Month | 6.99M |
| Short % of Shares Out | 10.26% |
| Short % of Float | 11.82% |
| Short Ratio (days to cover) | 7.16 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 618.07M |
| Gross Profit | 505.11M |
| Operating Income | -96.23M |
| Pretax Income | -857.54M |
| Net Income | -860.21M |
| EBITDA | -70.28M |
| EBIT | -96.23M |
| Loss Per Share | -$15.34 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 438.29M |
| Total Debt | 762.95M |
| Net Cash | -324.66M |
| Net Cash Per Share | -$5.00 |
| Equity (Book Value) | -10.42M |
| Book Value Per Share | -0.16 |
| Working Capital | 413.52M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -227.27M |
| Capital Expenditures | -1.47M |
| Depreciation & Amortization | 25.95M |
| Net Borrowing | 672.44M |
| Free Cash Flow | -228.74M |
| FCF Per Share | -$3.52 |
Margins
| Measure | Value |
|---|
| Gross Margin | 81.72% |
| Operating Margin | -15.57% |
| Pretax Margin | -138.75% |
| Profit Margin | -139.18% |
| EBITDA Margin | -11.37% |
| EBIT Margin | -15.57% |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -15.36% |
| Shareholder Yield | -15.36% |
| Earnings Yield | -17.89% |
| FCF Yield | -4.11% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $153.43 |
| Price Target Difference | 78.95% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 14 |
| Revenue Growth Forecast (3Y) | 27.01% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 1.32 |
| Piotroski F-Score | 3 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |